泽生科技

Shanghai Sci & Tech Committee and Shanghai Venture Capital Visited Zensun

2006-08-11

On March 18th, 2004, Zhu, Qigao and Dong, Shupei, Chair and Associate Chair of bio-therapeutical department, Shanghai Sci. and Tech. committee visited Zensun. Wang, Jianping, assistant Chair of modern biological and medicinal development office and Wang, Pingao CEO of Shanghai Venture Capital Co. Ltd. also joined this visit. They praised the results achieved by Zensun and provided constructive advice and promised the funding support for the research of Zensun’s two innovative drugs.

更多动态

Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas

ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA

ISS&ISE Reports Have Been Submitted to the FDA

Zensun Successfully Raised Approximately ¥504 million (US$76 million)

Zensun’s Listing Ceremony Held In Beijing For The Initial Listing Of Shares

ZS-07 shows positive results in an animal model of Alzheimer’s disease

Neucardin™ Phase III clinical trial (ZS-01-305) is now unblinding and analyzing data

Exciting results from the Neucardin™ Phase III clinical trial (Interim Analysis)

Zensun was presented “Frost & Sullivan´s 2016 Growth, Innovation and Leadership Awards”

Promising progress on a breakthrough therapy for severe heart failure

Mini-sonic and Portable Cardiogram Monitor by Zensun Will Be Commercialized in 2016

An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to

Zensun Announces Successful End of Phase 2 Meeting for Neucardin™

Zensun Announces Positive Results for Neucardin™ to Improve Heart Function and Reduce Mortality

Zensun Obtained the Exciting Results of US Phase II Clinical Trial

Phase II Clinical Trial of rhNRG-1 is Near Completion

Zensun has Submitted NDA of rhNRG-1 to SFDA

Chinese Phase III Clinical Trials of rhNRG-1 are Recruiting Patients

Zensun Sucessfully Finished New Round of Financing

Anti-Heart Failure Drug -- rhNRG-1 has Complete Chinese Phase II Clinical Trials

The Survival Study of rhNRG-1 Obtained Satisfying Result

rhNRG-1 Obtained SFDA Approval for Phase III Clinical Trial

Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1

Phase II Clinical Trials Results of rhNRG-1 have been Published in JACC

Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1

rhNRG-1 Phase II Clinical study Showed a Significant Decrease of Rehospitalization

An Article Published in Cell Demonstrated the Similar Mechanism as Zensun Discovered In July 24th

rhNRG-1 was Approved to Take Phase II Clinical Trial in US

Zensun Obtained Breakthrough Results in the Treatment of Heart Failure

Zensun was Reported by Media Worldwide

Zensun Completed Chinese Phase II Clinical Study of rhNRG-1

Zensun Finished Patients Recruitment of rhNRG-1’s Phase II b Clinical Trial in China

Zensun Achieved Important Progress in Australian Phase II clinical Trial

Effects of rhNRG-1 on Cardiac Function Improvements was Verified by the Recent Scientific Experiment

Zensun Obtained Initial Results of Australian Clinical Study

Minister of Science and Technology Visited Zensun

Zensun Successfully Passed the Mid-Term Evaluation of Science Prosperity Program

Article’s about rhNRG-1’s Animal Model Study was Commented by JACC Editors

Zensun Had a Meeting With the Expert Panel of FDA

Shanghai Sci & Tech Committee and Shanghai Venture Capital Visited Zensun

Zensun´s rhNRG-1 Project has passed the Preliminary Evaluation by Boehringer-Ingelheim

rhNRG-1 and rhErbB3-f were recognized as "Shanghai high-tech achievement transformation projects"

rhNRG-1 and rhErbB3-f were Selected to “Shanghai Sci & Tech Prosperity Program” and “Huiyan Program”

ABOUT ZENSUN

SCIENCE

Pipeline

INVESTOR RELATIONS

CAREERS

CONTACT US